RE "The following is a list of companies who have signed or are preparing to sign licenses to evaluate MultiCell's unique line of readily available, fully functional, immortalized hepatocytes:
Astra Zeneca, Aventis, Amgen, Bristol Myers Squibb, Eisai, Lilly, Novartis, Abbott, Bayer, Boehringer Ingleheim, Biogen, Genzyme, Glaxo Smith Kline, Johnson & Johnson, Hoffman LaRoche, Lexicon, Merck, Millenium, Neurogen, Shering Plough, Pfizer, Hoffman La Roche, Wyeth, Daiichi, Takeda (Japan’s largest pharma), Fujisawa, Ono, Mitsubishi, Shinogi, Sumitomo, Japan Tobacco"
That was from the original post here - July of 2004.
At the time, those companies were already in 90 day
evaluations. 2 (TWO) actually signed.
2 out of 31. Since then Xenotech never sent even the 1st of the quarterly minimum payments due this year, and there has
been a total of 3 different marketing methods attempted.
I'd call that a strikeout to say the least.
But nevermind, they're a stem cell company - no wait, now
they're a avian flu company because 3 years ago they worked
with mice on a different flu strain. No wait, they're a
med-tech company with a artificial liver device that's been
around for at least 8 years and hasn't entered phase 1 yet.
They're about out of money again and only God knows how many
millions of shares will be printed.
Do you guys honestly not see what a joke this company/stock is? |
